Psoriasis Clinical Trial
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
Summary
This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.
Eligibility Criteria
Inclusion Criteria:
Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient response to topical agents, and who meet the psoriasis assessment expectations as defined in the study protocol
Exclusion Criteria:
Females who are pregnant or breastfeeding
Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively
Subjects treated with leflunomide or other biological therapies to treat psoriasis and all JAK-STAT inhibitors within 12 weeks prior to first dose of study drug
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Hot Springs Arkansas, , United States
Los Angeles California, , United States
Clinton Minnesota, , United States
Fridley Minnesota, , United States
Rochester New York, , United States
Moncton New Brunswick, , Canada
Windsor Ontario, , Canada
Montreal Quebec, , Canada
Quebec , , Canada
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.